Life Technologies launches next-generation DNA and RNA quantitation system
Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced the launch of its next-generation Qubit(R) 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment.
- (1888PressRelease) November 30, 2010 - The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.
Precious samples are those that are rare, difficult to purify, or expensive to obtain or prepare, including clinical research samples or samples from laser-capture micro-dissection. Samples for applications that require a large financial or time investment are those that are extremely sensitive to sample conditions, such as high-throughput assays, or samples that may take an extended time or financial investment prior to obtaining results, such as transfection.
New features of the Qubit 2.0 Fluorometer include a LCD color touch screen, a USB port, and architecture to allow efficient data management. Because of these features, the new Qubit 2.0 Fluorometer is easier to use and navigate with touch screen and buttons always present to easily view workflow and provide a way to save and then export a CSV data file without losing any of the high sensitivity, accuracy, or precision of the original instrument.
"We've continued to innovate one of the biggest advancements in quantitation in more than 40 years," said Nicolas Barthelemy, President of Cell Systems at Life Technologies. "We've made the platform easier to use without sacrificing the accuracy and sensitivity of the system. Qubit 2.0 is the benchtop instrument of choice for molecular biologists using delicate samples and who can't afford an error in quantifying the amount of DNA, RNA or protein."
The Qubit 2.0 Fluorometer can easily be utilized in workflows upstream of a range of other research use instrumentation in the Life Technologies portfolio, including the 7500 Fast Real-Time PCR Instrument for amplification and precise quantification of nucleic acids, and the Neon Transfection Device, which facilitates the delivery of DNA, RNA and proteins into difficult-to-transfect cells such as stem cells.
Qubit 2.0 Fluorometer, the 7500 Fast, and Neon instruments are For Research Use Only. Not for use in diagnostic procedures.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Corporation
Lauren Lum
650-638-6916
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam